Skip to main content

Table 3 Complete response of CINV in different grade

From: Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting

 

Complete response (%)

 

AN

AV

DN

DV

 

L1

L2

L1

L2

L1

L2

L3

L1

L2

L3

TG

96.70

97.52

97.52

99.17

90.08

94.21

100

93.39

96.70

100

CG

100

87.04

97.22

91.66

82.40

62.96

99.07

89.81

76.85

99.07

P value

> 0.05

< 0.05

> 0.05

< 0.05

> 0.05

< 0.05

> 0.05

> 0.05

< 0.05

> 0.05

  1. Definition of nausea according to CTCAE V 3.0
  2. L1: Loss of appetite without alteration in eating habits
  3. L2: Oral intake decreased without significant weight loss, dehydration or malnutrition; IV fluids, indicated < 24 hrs.
  4. L3: inadequate oral caloric and/or fluid intake, IV fluids, tube feedings, or TPN indicated ≥ 24 hrs
  5. L4: Life-threatening consequences
  6. L5: Death
  7. Definition of nausea according to CTCAE V 3.0
  8. L1: 1 episode in 24 hrs
  9. L2: 2-5 episodes in 24 hrs; IV fluids indicated < 24 hrs
  10. L3: > = 6 episodes in 24 hrs; IV fluids, or TPN indicated > = 24 hrs
  11. L4: Life-threatening consequences
  12. L5: Death